Entera Bio Ltd. (ENTX)
Entera Bio Statistics
Share Statistics
Entera Bio has 45.42M shares outstanding. The number of shares has increased by 16.52% in one year.
| Shares Outstanding | 45.42M |
| Shares Change (YoY) | 16.52% |
| Shares Change (QoQ) | 13.31% |
| Owned by Institutions (%) | 19.95% |
| Shares Floating | 32.05M |
| Failed to Deliver (FTD) Shares | 382 |
| FTD / Avg. Volume | 0.67% |
Short Selling Information
The latest short interest is 73.12K, so 0.2% of the outstanding shares have been sold short.
| Short Interest | 73.12K |
| Short % of Shares Out | 0.2% |
| Short % of Float | 0.23% |
| Short Ratio (days to cover) | 2 |
Valuation Ratios
The PE ratio is -8.37 and the forward PE ratio is 8.81. Entera Bio's PEG ratio is 0.43.
| PE Ratio | -8.37 |
| Forward PE | 8.81 |
| PS Ratio | 440.99 |
| Forward PS | 1.8 |
| PB Ratio | 9.88 |
| P/FCF Ratio | -11.7 |
| PEG Ratio | 0.43 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Entera Bio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.63, with a Debt / Equity ratio of 0.03.
| Current Ratio | 7.63 |
| Quick Ratio | 7.63 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.03 |
| Debt / FCF | -0.04 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $10.06K |
| Profits Per Employee | $-530.06K |
| Employee Count | 18 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 14K |
| Effective Tax Rate | 0.15% |
Stock Price Statistics
The stock price has increased by 5.74% in the last 52 weeks. The beta is 1.48, so Entera Bio's price volatility has been higher than the market average.
| Beta | 1.48 |
| 52-Week Price Change | 5.74% |
| 50-Day Moving Average | 1.91 |
| 200-Day Moving Average | 1.94 |
| Relative Strength Index (RSI) | 63.31 |
| Average Volume (20 Days) | 56.65K |
Income Statement
In the last 12 months, Entera Bio had revenue of 181K and earned -9.54M in profits. Earnings per share was -0.25.
| Revenue | 181K |
| Gross Profit | 9K |
| Operating Income | -9.59M |
| Net Income | -9.54M |
| EBITDA | -9.59M |
| EBIT | -9.59M |
| Earnings Per Share (EPS) | -0.25 |
Balance Sheet
The company has 8.66M in cash and 272K in debt, giving a net cash position of 8.39M.
| Cash & Cash Equivalents | 8.66M |
| Total Debt | 272K |
| Net Cash | 8.39M |
| Retained Earnings | -113.93M |
| Total Assets | 9.39M |
| Working Capital | 7.8M |
Cash Flow
In the last 12 months, operating cash flow was -6.82M and capital expenditures -3K, giving a free cash flow of -6.82M.
| Operating Cash Flow | -6.82M |
| Capital Expenditures | -3K |
| Free Cash Flow | -6.82M |
| FCF Per Share | -0.18 |
Margins
Gross margin is 4.97%, with operating and profit margins of -5295.58% and -5271.27%.
| Gross Margin | 4.97% |
| Operating Margin | -5295.58% |
| Pretax Margin | 5263.54% |
| Profit Margin | -5271.27% |
| EBITDA Margin | -5295.58% |
| EBIT Margin | -5295.58% |
| FCF Margin | -3768.51% |
Dividends & Yields
ENTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ENTX is $10, which is 352.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 352.5% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | 27.68 |
| Piotroski F-Score | 3 |